The HEOR strategic shift means health economics and outcomes research has to change where its influence is earned. After three decades spent defining a discipline, building standards and filling journals, the field faces a harder test: whether its evidence reaches the rooms where coverage, pricing and resource allocation are decided. For executives in health economics, market access, pricing strategies and policy, the stakes are practical: how value is framed, how budget impact is defended, and how reimbursement decisions are shaped over a product’s full life cycle.

Why the traditional endpoint no longer holds

For most of its history, ISPOR and the wider community treated rigorous analysis and peer-reviewed acceptance as the natural close of the work. That foundation still holds, but the finish line has moved. Publication on its own does not secure formulary placement, inform value-based pricing or alter how systems behave. Practitioners still need technical depth, and they also need to put models inside real-world problems and explain, in plain language, why one decision beats another. Evidence generation has to continue; translation and communication need a larger share of the time and talent available.

C-suite interviews and return-on-investment work point to the same perception. Many leaders still see HEOR as a source of statistical and cost-effectiveness models rather than of narrative that executives can use to manage growth, risk and market access. Academic training has long privileged technique over audience awareness and plain-language craft. The function therefore gets treated as a downstream launch task rather than an early development driver, which costs money when reimbursement hurdles appear late and there is no time left to correct course.

Stakeholders, capital and the widening tent

Progress depends on who sits inside the conversation. Payers, clinicians and chief executives have not been engaged at the scale the work now requires. Token panel appearances are a beginning. The stronger ambition is to convene payers from several jurisdictions together so that differences in decision logic become visible and HEOR can adjust what it offers. Engagement works when it starts from what each group is struggling with.

Investors hold a quieter but decisive position. Small and mid-sized life-sciences firms depend on their capital, so there is a case for presenting HEOR as an ally that de-risks early pipelines and shows commercial adoption potential well before phase III. Biotech leaders without in-house HEOR capacity are already asking what the society and the discipline can offer. The answer has to be evidence of value beyond clinical efficacy, put in terms that make sense to people who allocate capital rather than to methodologists alone. The models themselves are strong; what fails is the communication of their conclusions to boards and investors.

Lifecycle evidence, adaptive access and policy implications

Policy implications of this HEOR strategic shift are already visible in pricing and coverage practice. Medicare drug price negotiation has turned evidence generation from a one-off milestone at launch into a continuous requirement across the product life cycle. Manufacturers must sustain comparative effectiveness, economic and real-world data for years after entry if they are to justify maximum fair price against evolving alternatives. Comparator choice, accumulated real-world evidence and a durable value story now sit at the centre of pricing strategies and long-term budget impact management.

Artificial intelligence, large language models and, eventually, quantum computing are compressing what used to be sequential hurdles. Approval, coverage and pricing look more like an adaptive feedback loop supported by living evidence than a single clearance event. Reassessment should follow material shifts in clinical or economic certainty: mature phase III results, real-world safety or effectiveness that diverges from trial data, major budget impact, or a new competitive standard of care. Companies and health systems that work in a straight line will struggle against competitors that treat evidence as something that changes.

Joint clinical assessment under European Union HTA regulation pushes the same logic outward. Well-prepared firms bring clinical development, market access and regulatory teams together years before pivotal trial design. Treating joint clinical assessment as a compliance exercise, underestimating PICO burden, delaying real-world evidence or ignoring national differences weakens the access goals the regulation claims to serve. A pan-European evidence platform still has to land inside distinct payer contexts if reimbursement decisions are to hold up.

Real-world evidence shows both the promise and the limits. It has strengthened post-market safety surveillance, as the FDA Sentinel Initiative’s use of linked records, claims and registries demonstrates, and it has supported label expansion in rare disease and pragmatic comparative work. It has also been oversold when retrospective, weakly controlled studies chase efficacy mimicry without serious bias control. Data quality, design transparency and shared best practice, work begun with ISPE, remain the conditions of credibility. Pairing artificial intelligence with real-world evidence may unlock further gains, provided the weaknesses underneath are not simply amplified.

System design, US fragmentation and institutional response

System dynamics in the United States remain shaped by a fragmented mix of private payers, federal programmes such as CMS, and independent groups including ICER that carry out quasi-HTA work. A single central agency with authority over national pricing and reimbursement would be hard to establish quickly in a system this large and complex. A coordinated set of bodies building on existing CMS and ICER practice is a more plausible near-term route to clearer value metrics, less regional disparity and more coherent infrastructure. Politics and electoral cycles will limit how far any change can go, which is an argument for designing stepwise options rather than accepting the present mix as good enough.

What decision-makers should do next

HEOR and market access leaders should treat the HEOR strategic shift as an operating mandate. Build translation skills, business fluency and audience-aware communication into professional development so that technical output connects visibly to launch planning, portfolio choices and risk mitigation. Integrate HEOR, medical affairs and market access at phase I or II; late engagement predictably delays access and adds budget impact that could have been avoided. Pricing teams should plan comparative and real-world evidence as a life-cycle asset that can survive repeated negotiation and reassessment, not as a single dossier. Payers and HTA bodies should favour transparent, co-created processes that combine trial and real-world inputs and reduce fragmentation through coordination, even where full centralisation stays out of reach. Manufacturers facing rising evidence demands while teams have been restructured need to look at capacity honestly: the requirements are growing more complex, not less. Investors and biotech chiefs should treat focused summits as working sessions on specific pain points rather than conventional conferences.

Frequently Asked Questions

What does the HEOR strategic shift mean for pricing teams?

It requires treating evidence as a living asset that supports repeated negotiations and reassessments across a product’s lifecycle rather than a one-time launch dossier.

How can companies prepare for joint clinical assessment under EU HTA rules?

Align clinical development, market access and regulatory teams early, account for national PICO differences and build real-world evidence plans well before pivotal trials begin.

Why should investors pay attention to HEOR outputs?

Strong HEOR communication de-risks pipelines by demonstrating commercial adoption potential and value beyond clinical efficacy to boards and capital allocators.